Reviva Pharmaceuticals Holdings Stock Current Valuation
| RVPH Stock | USD 1.04 0.06 5.45% |
Valuation analysis of Reviva Pharmaceuticals helps investors to measure Reviva Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. The Reviva Pharmaceuticals' current Enterprise Value is estimated to increase to about 93.7 M, while Enterprise Value Over EBITDA is forecasted to increase to (0.000002). Fundamental drivers impacting Reviva Pharmaceuticals' valuation include:
Overvalued
Today
Please note that Reviva Pharmaceuticals' price fluctuation is extremely dangerous at this time. Calculation of the real value of Reviva Pharmaceuticals is based on 3 months time horizon. Increasing Reviva Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Reviva Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Reviva Stock. However, Reviva Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.04 | Real 1.0 | Target 12.57 | Hype 1.04 | Naive 1.24 |
The intrinsic value of Reviva Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Reviva Pharmaceuticals' stock price.
Estimating the potential upside or downside of Reviva Pharmaceuticals Holdings helps investors to forecast how Reviva stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Reviva Pharmaceuticals more accurately as focusing exclusively on Reviva Pharmaceuticals' fundamentals will not take into account other important factors: Reviva Pharmaceuticals Holdings Company Current Valuation Analysis
Reviva Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Reviva Pharmaceuticals Current Valuation | 42.73 M |
Most of Reviva Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Reviva Pharmaceuticals Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Reviva Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Reviva Pharmaceuticals is extremely important. It helps to project a fair market value of Reviva Stock properly, considering its historical fundamentals such as Current Valuation. Since Reviva Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Reviva Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Reviva Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Reviva Current Valuation Historical Pattern
Today, most investors in Reviva Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Reviva Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Reviva Pharmaceuticals current valuation as a starting point in their analysis.
Reviva Pharmaceuticals Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Reviva Pharmaceuticals Holdings has a Current Valuation of 42.73 M. This is 99.7% lower than that of the Biotechnology sector and 99.08% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.74% higher than that of the company.
Reviva Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Reviva Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Reviva Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Reviva Pharmaceuticals by comparing valuation metrics of similar companies.Reviva Pharmaceuticals is currently under evaluation in current valuation category among its peers.
Reviva Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Reviva Pharmaceuticals from analyzing Reviva Pharmaceuticals' financial statements. These drivers represent accounts that assess Reviva Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Reviva Pharmaceuticals' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 26.8M | 42.7M | 82.9M | 122.6M | 110.3M | 115.8M | |
| Enterprise Value | 18.0M | 13.1M | 64.4M | 99.2M | 89.3M | 93.7M |
Reviva Fundamentals
| Return On Equity | -17.95 | ||||
| Return On Asset | -3.28 | ||||
| Current Valuation | 42.73 M | ||||
| Shares Outstanding | 46.58 M | ||||
| Shares Owned By Insiders | 14.30 % | ||||
| Shares Owned By Institutions | 29.40 % | ||||
| Number Of Shares Shorted | 4.25 M | ||||
| Price To Book | 8.35 X | ||||
| EBITDA | (39.5 T) | ||||
| Net Income | (39.26 M) | ||||
| Cash And Equivalents | 23.19 M | ||||
| Cash Per Share | 1.13 X | ||||
| Total Debt | 17.98 M | ||||
| Current Ratio | 6.72 X | ||||
| Book Value Per Share | (0.30) X | ||||
| Cash Flow From Operations | (28.32 M) | ||||
| Short Ratio | 2.72 X | ||||
| Earnings Per Share | (1.08) X | ||||
| Target Price | 12.14 | ||||
| Number Of Employees | 15 | ||||
| Beta | -0.099 | ||||
| Market Capitalization | 48.44 M | ||||
| Total Asset | 23.7 M | ||||
| Retained Earnings | (134.35 M) | ||||
| Working Capital | 6.53 M | ||||
| Net Asset | 23.7 M |
About Reviva Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Reviva Pharmaceuticals Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Reviva Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Reviva Pharmaceuticals Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Reviva Pharmaceuticals is a strong investment it is important to analyze Reviva Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Reviva Pharmaceuticals' future performance. For an informed investment choice regarding Reviva Stock, refer to the following important reports:Check out Reviva Pharmaceuticals Piotroski F Score and Reviva Pharmaceuticals Altman Z Score analysis. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Reviva Pharmaceuticals. If investors know Reviva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Reviva Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Reviva Pharmaceuticals is measured differently than its book value, which is the value of Reviva that is recorded on the company's balance sheet. Investors also form their own opinion of Reviva Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Reviva Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Reviva Pharmaceuticals' market value can be influenced by many factors that don't directly affect Reviva Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Reviva Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Reviva Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Reviva Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.